Merit Financial Group, LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 18 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Merit Financial Group, LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2023$9,8000.0%10,0000.0%0.00%
Q4 2022$9,800
-2.0%
10,0000.0%0.00%
Q3 2022$10,0000.0%10,0000.0%0.00%
Q2 2022$10,000
+11.1%
10,0000.0%0.00%
-100.0%
Q1 2022$9,000
-10.0%
10,0000.0%0.00%0.0%
Q4 2021$10,000
+11.1%
10,0000.0%0.00%0.0%
Q3 2021$9,0000.0%10,0000.0%0.00%0.0%
Q2 2021$9,000
+12.5%
10,0000.0%0.00%0.0%
Q1 2021$8,0000.0%10,0000.0%0.00%0.0%
Q4 2020$8,0000.0%10,0000.0%0.00%0.0%
Q3 2020$8,000
+14.3%
10,0000.0%0.00%0.0%
Q2 2020$7,000
-12.5%
10,0000.0%0.00%0.0%
Q1 2020$8,000
-20.0%
10,0000.0%0.00%0.0%
Q4 2019$10,000
+11.1%
10,0000.0%0.00%0.0%
Q3 2019$9,00010,0000.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2023
NameSharesValueWeighting ↓
Man Investments (CH) AG 3,300,000$2,640,0002.48%
SYMPHONY ASSET MANAGEMENT LLC 14,000,000$11,200,0001.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 36,000,000$28,879,0001.14%
Opera Trading Capital 5,500,000$4,344,0000.89%
MACKAY SHIELDS LLC 17,789,000$14,221,0000.52%
TENOR CAPITAL MANAGEMENT Co., L.P. 6,000,000$4,918,0000.37%
ADVENT CAPITAL MANAGEMENT /DE/ 24,415,000$19,539,0000.37%
OAKTREE CAPITAL MANAGEMENT LP 28,415,000$22,732,0000.36%
GLG Partners LP 8,700,000$6,960,0000.33%
HIGHFIELDS CAPITAL MANAGEMENT LP 42,285,000$33,828,0000.28%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders